Bangalore: The death of 49 babies in clinical trials at the All India Institute of Medical Sciences (AIIMS) in New Delhi may have opened a Pandora’s box as two of the trial drugs have never been tried on patients below 18 years, an expert said. How many of the children died because of the trial […]
Indian subjects in clinical trials are vulnerable lot
The government of India enacted a new rule that allows foreign pharmaceutical companies and other interested parties to conduct trials of new drugs in India during the same time that trials of the same phase are being conducted in other countries. But even under the new rule, phase 1 trials will not normally be permitted […]
India is Becoming the Hub of Clinical Trials
It might take somewhere between 10 and 15 years for the drug development process from pre-clinical to complete phase III clinical trials. Out of which, the phase II and III clinical trials consume almost half of the time. Given this situation, it looks imperative that pharmaceutical and biotechnology companies ought to look for ways to […]
Children’s Hospital of Michigan DMC Research Team Leads Cardiology Component of Clinical Trial to Protect the Hearts of Children Who Receive Chemotherapy
Published in the upcoming March 10, 2016 issue of the authoritative Journal of Clinical Oncology, this new study is likely to change the standard of cardiac care during treatment of many childhood cancer patients. After more than two decades of grueling research on a National Institutes of Health study, Children’s Hospital of Michigan Pediatrician-in-Chief and […]
PAREXEL Enhances ClinPhone® RTSM Service To Simplify And Expedite Randomisation And Trial Supply Management For Clinical Studies
London, 27 May, 2015 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced enhancements to its Randomisation and Trial Supply Management (RTSM) service, ClinPhone® RTSM. PAREXEL designed the enhanced service to simplify patient randomisation and clinical supply management and to offer greater speed and flexibility in tailoring the service to […]
Molmed TK ASH: Long term assessment of TK clinical benefit at the 54th Annual Meeting
Milan (Italy), 10 December 2012 – MolMed S.p.A. (MLM.MI) announces the presentation of the long term clinical benefit and safety data of its investigational cell-based therapy TK at the 54th Annual Meeting of the American Society of Hematology (ASH) in Atlanta (GA, U.S.). The overall analysis comprises 128 patients with high-risk haematological malignancies who were treated in different […]
- 1
- 2
- 3
- …
- 21
- Next Page »